An experimental vaccine increases survival rates by up to 50% in four people with highly-aggressive brain cancer

Four patients with glioblastoma lived up to 50% longer than expected with the experimental vaccine personalized for each individual.

The vaccine uses lipid particles containing genetic information from the patient's tumor, training the immune system to recognize and fight cancer cells like viruses.

Patients on standard treatment survived around six months, but vaccine recipients reached nine and eight months, showing significant benefits.

University of Florida researchers plan a larger trial with 24 patients and a subsequent trial focusing on children to validate safety and efficacy of the vaccine.

Read at english.elpais.com